Lunai Bioworks Inc (LNAI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.39+1.70%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LNAI
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on deploying AI-enabled chemical threat assessment and expanding biodefense capabilities including biological threat detection and countermeasure development.
Newly stated in 2026-Q2. Management announced the first revenue-generating defense contract for chemical threat assessment and plans to expand biodefense capabilities. Financials show continued net losses and negative operating income, indicating early-stage investment. The trajectory is nascent with initial contract secured but no revenue growth data yet.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 3 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“We secured our first revenue-generating, multi-year defense collaboration through BioSymetrics for chemical threat assessment.”
Develop AI-driven therapeutics in epilepsy, Parkinson's, and Alzheimer's with external collaborations and NIH-supported research.
Newly stated in 2026-Q2. Management highlighted progress in precision neurology with external collaborations and a $1.85 million NIH grant. Financials show ongoing net losses and negative operating income, consistent with early-stage R&D investment. The trajectory is early but supported by external funding.
“Advancing collaborations including partnership with BrainStorm Therapeutics and NIH-supported Phase I/II STTR grant for alcohol use disorder research.”
Initiate and vigorously pursue legal action against parties engaged in naked short selling to restore shareholder value.
Newly stated in 2026-Q2. Management disclosed litigation to address naked short selling involving 29.6 million shares (81.6% of outstanding shares). This is a strategic priority to protect shareholder interests amid ongoing net losses and negative operating income. The trajectory is initial legal action with discovery underway.
“In May 2026, we initiated legal action in U.S. District Court against parties alleged to have engaged in naked short selling.”
Implement measures including reverse stock splits to regain compliance with Nasdaq minimum bid price and listing rules.
Newly stated in 2026-Q1. Management executed a 1-for-8 reverse stock split to increase share price and regain Nasdaq compliance. Prior reverse split was 1-for-10 in 2025-Q3. Despite these actions, the company remains under financial stress with net losses and negative operating income. The trajectory shows active efforts to comply but ongoing regulatory challenges.
“Announced 1-for-8 reverse stock split to increase market price and regain Nasdaq compliance.”
Finalize acquisition and integration of Oncotelic Inc. and Pelerin Therapeutics Inc. to enhance strategic position.
Newly stated in 2026-Q2. Management completed acquisition of Oncotelic and Pelerin by issuing Series B Preferred Stock valued at $20 million. This strategic move is recent with no financial impact yet visible in revenue or income. The trajectory is initial completion with integration to follow.
“On May 1, 2026, issued Series B Preferred Stock to Oncotelic and Pelerin as merger consideration.”
Over the trailing year it converted 0.11x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
40 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.